Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
RecruitingLast updated: 2 February 2024
Clinical summaryEligibilityParticipating hospitalsSupport
Clinical summary
Summary
Eligible patients will be randomised into one of three arms of the study. Arm A: participants will receive treatment with Durvalumab + Oleclumab, Arm B: participants will receive treatment with Durvalumab + Monalizumab, and Arm C: participants will receive Durvalumab and a placebo.
Conditions
This trial is treating patients with non-small cell lung cancer
Cancer
Lung cancer
Age
18+
Phase
III
Trial Acronym
PACIFIC-9
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
- NCT05221840
- D9078C00001
Trial sponsor
AstraZeneca
Scientific Title
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Share with email
Print this page
Glossary
Eligibility
Inclusion
- Participant must be ≥ 18 years at the time of screening.
- Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
- Provision of a tumour tissue sample obtained prior to CRT
- Documented tumour PD-L1 status by central lab
- Documented EGFR and ALK wild-type status (local or central).
- Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy
- Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
- Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
- WHO performance status of 0 or 1 at randomization
- Adequate organ and marrow function
Exclusion
- History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.
- Mixed small cell and non-small cell lung cancer histology.
- Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
- Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
- Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
- Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.
- History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
Inclusion
- Your cancer has spread to other parts of the body.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
Participating hospitals
Recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Get Support
Cancer Connect
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Learn more
Cancer Council’s cancer nurses
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Learn more
Information for family, friends and carers
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Learn more
Report inaccuracy
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.
Submitting ... Please wait
";}});$(this).html(itemList);});//Sort Hospital Alphabetically$("#TrialDetails-Hospitals .sites").each(function(){var sortHospitals = $(this).children(".site").sort(function(a, b) {return String.prototype.localeCompare.call($(a).data('site').toLowerCase(), $(b).data('site').toLowerCase());});$(this).empty().append(sortHospitals);});//Download Resources//$("#Trials-Tools-Booklet").css("display","none");//if (valueExists($("#Trials-CancerStream").html())) //{//$.ajax({type: "GET", url: "/downloads/feeds/keywords.json?version=20240530",async: false,//success: function(response)//{//var itemArray = ($("#Trials-CancerStream").html() + ",").split(",");//$.each(response, function (key, val) {//if(valueExists(val.cancertype.trim()))//{//$.each(itemArray, function(cncrKey,cncrValue) { //if(valueExists(cncrValue) && (cncrValue == val.cancertype.trim()) && valueExists(val.resourcelink)) //{ //$("#Trials-Tools-Booklet").css("display","inline-block");//$("#Trials-Tools-Booklet a").attr("href",val.resourcelink);//return false;//}//});//}//});//}//});//}//Conflicting Inclusion statement - Append ORif($("#TrialDetails-Eligibility .cols-2 .col.first ul").length > 0){var conflictFound = false;$('#TrialDetails-Eligibility .cols-2 .col.first ul li').each(function(index, item) {if(!conflictFound && (($(this).html() == "Your cancer has not spread to other parts of the body.") || ($(this).html() == "Your cancer has spread to other parts of the body."))){conflictFound = true;}else if(conflictFound && (($(this).html() == "Your cancer has not spread to other parts of the body.") || ($(this).html() == "Your cancer has spread to other parts of the body."))){$("#TrialDetails-Eligibility .cols-2 .col.first ul li:eq(" + (index-1) + ")").append("
");}});}});//Sticky tab menu$(window).scroll(function(){pageOffsetTop = $(this).scrollTop();if(pageOffsetTop >= headerOffset) { $("#TrialDetails-Tabs").addClass("sticky"); } else {$("#TrialDetails-Tabs").removeClass("sticky"); }});//Print pagefunction printThisPage(){window.print();}//Feedback Form Validationfunction ValidateTrialFeedbackForm() {var validForm = true, emailFormat = /^\w+([\.-]?\w+)*@\w+([\.-]?\w+)*(\.\w{2,3})+$/;;if (typeof (Page_ClientValidate) == 'function') {Page_ClientValidate("formValidateFeedbackGroup");validForm = validForm && Page_IsValid;}if (validForm) { $("#formWrapper .fieldSubmitButton input[type=submit]").css("display", "none"); $("#formWrapper .fieldSubmitButton .fieldSubmitButtonStatus").css("display", "inline-block"); }return true;}
